Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 171 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IPA Clear all
Completed Not applicable Interventional Results available

EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron

NCT02618343
View directory record Official record
Conditions
Nausea
Interventions
IPA, Ondansetron
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
View directory record Official record
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516
View directory record Official record
Conditions
Muscle Weakness
Interventions
HMB, hydroxymethylbutyrate, EPA, eicosapentaenoic acid, Saline
Drug
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of VisionPure™ on Indices of Vision Health and Cognitive Function

NCT05533658
View directory record Official record
Conditions
Eye Health, Vision, Cognitive Function
Interventions
VisionPure Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Lutz, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Prasugrel Versus Placebo in Adult Sickle Cell Disease

NCT01167023
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

NCT01633177
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
22,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

NCT00361374
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
eicosapentaenoic acid, docosahexaenoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 29, 2026, 1:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study

NCT01400490
View directory record Official record
Conditions
Heart Disease
Interventions
EPA-DHA Study
Dietary Supplement
Lead sponsor
Cardiovascular Research Associates
Network
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Anxiety and Anorexia Nervosa in Adolescents

NCT01933243
View directory record Official record
Conditions
Anxiety, Anorexia Nervosa
Interventions
Fish oil, Placebo pill
Drug
Lead sponsor
Andrea Bonny
Other
Eligibility
12 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

NCT01704859
View directory record Official record
Conditions
Fractures
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

NCT02578771
View directory record Official record
Conditions
Surgical Site Infection
Interventions
ZuraPrep with 70% IPA, ZuraPrep without 70% IPA, ChloraPrep CHG/IPA Teal Tint, Normal Saline
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 29, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

NCT03672292
View directory record Official record
Conditions
Invasive Pulmonary Aspergillosis
Interventions
SCY-078, Voriconazole, Oral Placebo Tablets
Drug · Other
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Fatty Acid Supplementation in Children With ASD (Study 2)

NCT04312932
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 29, 2026, 1:03 AM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

NCT02859129
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

NCT00001146
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Ethyl Eicosapentaenoic Acid, OmegaBrite
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

NCT02670382
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA, DHA, sunflower oil
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 29, 2026, 1:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 29, 2026, 1:03 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

VITAL Rhythm Study

NCT02178410
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Vitamin D3, Omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D3 placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

NCT01308710
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Omega-3 fatty acid (Eicosapentaenoic acid)
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Patient Preoperative Prep

NCT02831816
View directory record Official record
Conditions
Surgical Skin Preparation
Interventions
ZuraPrep, ChloraPrep, ZP Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
n-3 polyunsaturated fatty acids, Placebo
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 29, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

NCT06967129
View directory record Official record
Conditions
Astigmatism
Interventions
Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent., ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
20
States / cities
Mission Viejo, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 1:03 AM EDT